Regulatory Reforms: Denmark

Camilla C. Collet

Signe Alfasten

Regulatory Reforms

01/06/2024

Gorrissen Federspiel / Denmark

The ins and outs of regulatory reforms in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119.

1. Are there proposals for reform or significant change to the healthcare system?

N/A.

2. When are they likely to come into force?

N/A.

<

Also From This Contributor

Regulatory, Pricing and Reimbursement: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

The legal framework for regulatory, pricing and reimbursement of drugs in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country? The Danish Ministry of Health is responsible for defining the overall framework for the national healthcare system. As a governmental body…

Preclinical and Clinical Trial Requirements: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

Preclinical and clinical trial requirements in Denmark – an overview. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. Are clinical trials required to be conducted locally as a condition (stated or implicit) for marketing approval? No, clinical trials are not required to be conducted locally as a condition for a marketing authorization. As a starting point, an application for…

Marketing, Manufacturing, Packaging & Labeling, Advertising: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

A brief overview of the situation regarding marketing, manufacturing, packaging & labeling, advertising in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What is the authorization process for the marketing of new drugs, biologics, medical devices, over-the-counter medications, and other medicinal products? Please see Question 3 of Regulatory, Pricing and Reimbursement Overview. 2. What is the authorization…

Traditional Medicines and OTC Products: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

Key legal info on traditional medicines and OTC products in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What are the regulatory requirements for traditional, herbal, complementary, or alternative medicines and devices? Natural medicinal products, traditional herbal medicinal products, homeopathic medicinal products, and strong vitamin and mineral products are all special categories of medicinal products and are as…

Patents and Trademarks: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

The low-down on the situation regarding patents and trademarks in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What are the basic requirements to obtain patent and trademark protection? Patents In Denmark, a patent can be obtained by i) filing of a patent application with the Danish Patent and Trademark Office (“DKPTO”), ii) filing a patent application according…

Cannabinoid Drugs, Medicinal Cannabis and Opioid Drugs: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

An intro to the legal situation for cannabinoid drugs, medicinal cannabis and opioid drugs in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your country? Cannabinoid drugs, i.e. medicinal products where the active substance is cannabinoids, can be authorised in Denmark in accordance with the general rules on development, manufacture and…

Localization: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

Keen to learn more about localization in Denmark? Read on! Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. Are there any rules or regulations requiring and/or encouraging localization in your country? What is the legal framework defining these localization rules and policies? No, as a starting point there are no rules or regulations formally requiring localization in…

Orphan Drugs and Rare Diseases: Denmark

01/06/2024

Gorrissen Federspiel

Denmark

An insight into orphan drugs and rare diseases in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What is the definition of Rare Diseases in your country? Pursuant to Regulation (EC) no. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (“Orphan Drug Regulation”), a medicinal product may be designated…

Product Liability: Denmark

01/02/2024

Gorrissen Federspiel

Denmark

All legal aspects surrounding product liability. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. What types of liability are recognized in your jurisdiction? Generally, a person or company may incur liability by way of (i) contractual liability or (ii) civil liability due to violations of statutory law and/or culpable behaviour. Depending on the wording of the contractual terms giving rise…

Biosimilars and Biologics: Denmark

19/10/2022

Gorrissen Federspiel

Denmark

Key legal info on biosimilars & biologics in Denmark. Prepared in association with Gorrissen Federspiel, a leading law firm in Denmark, this is an extract from The Pharma Legal Handbook: Denmark, available to purchase here for GBP 119. 1. Are biosimilar medicines considered the same as generic medicines in your country? No. A biosimilar medicinal product is a new version of an existing biological medicinal product (i.e. a medicinal product is derived from a biological source). Biosimilar products are…

Healthcare System and Funding: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Please make a general introduction to the public health sector in your country and its organization The Danish healthcare system The Danish public healthcare system is universal – all registered Danish residents are automatically enrolled in the publicly financed system – and it is based on the principles of free and equal access to healthcare. The public healthcare system operates across three overall…

Healthcare Actors and Payers: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Which are the administrations, bodies and institutions in charge of public health in your country and what are their respective responsibilities? As mentioned, the Danish public healthcare system operates across three levels: the national level (the state), the regional level (the five Danish regions), and the local level (the 98 municipalities). The Danish public healthcare system is decentralized; while the government sets the…

Post Market-Approval Processes and Regulations: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. What are the pricing principles and processes in your country? As mentioned above, there are two main markets for medicines in Denmark: the primary healthcare sector (prescription medicines) and the secondary sector (hospitals). A third market consists with respect to the retail sale of certain over-the-counter medicines. The companies placing the medicinal products on the Danish market are in principle free to set…

Price Control and Reference Pricing Systems: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Which are the health technology assessment (HTA) evaluation bodies and their responsibilities in your country? The Danish Medicines Council New medicines (or product with new indications) that are intended for the Danish hospital market, must first be assessed by the Danish Medicines Council. The objective of the Danish Medicines Council is to provide guidance and recommendations on new medicines and standard therapies used in…

HTA Decision Analysis Framework: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Taken from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on the HTA decision analysis framework in Denmark. Buy The Pharma Legal Handbook: Market Access & HTA – Denmark here for £359. Which are the health technology assessment (HTA) evaluation bodies and their responsibilities in your country? The Danish Medicines Council New medicines (or product with new indications) that are intended for the Danish hospital market, must first be assessed…

Expenditure Control and Cost-Containment Policies: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Please describe the main cost containment policies in place in your country and their fundamental principles On an overall level, control of healthcare expenditures is based on budget laws and annual agreements between the Danish state, the regions and the municipalities. Primary sector Within the primary sector, cost containment measures include the Danish substitution system, price-cap agreements, and limitations on permitted discounts/rebates that…

HTA Dossiers: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Have local authorities published recommendations/guidelines surrounding value assessment dossiers? (If yes please add link) The Danish Medicines Agency has published two main guidelines: i) The Danish Medicines Council’s process guide for assessing new pharmaceuticals; and ii) The Danish Medicines Council methods guide for assessing new pharmaceuticals, which clarify the requirements for companies wanting to have a new medicine or extension of indication for…

Managed Entry Agreements: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Are there any Managed entry agreements in place in your country? (If so, please list them) There have been examples of use of managed entry agreements in Denmark. For example, Amgros may enter into agreements with pharmaceutical companies with terms concerning payment upon documentation of results (efficacy and safety), terms related to discounts, a cap on annual expenditures. Further, there has in the…

Public Procurement and Tendering: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Which are the main actors involved in public procurement and tendering? During the tender: The main actors involved in a public tender are the contracting authority, i.e., the authority that needs to procure a product or a service and thus initiates the tender process, and the tenderers, i.e. the suppliers/companies who submit bids to the tender. In Denmark, public tenders are conducted primarily…

Essential Drug List: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. Has an essential or priority drug list been published in your country? (If so provide the link) The guideline process of the Danish Medicines Council results in recommendations with prioritized list of medicines to be used for patients with specific diseases. The guidelines and recommendations are available on the Danish Medicines Council’s website: https://medicinraadet.dk/anbefalinger-og-vejledninger?page=&order=&take=&currentpageid=1095&database=1095&secondary=&q=&period=0 Hospital drug formularies (secondary care) are also widely used…

Orphan Drugs: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. What is the definition of an orphan drug in your country? The term “orphan drug” usually refers to medicins used for rare diseases – i.e. diseases where the prevalence of the condition in the EU is not more than 5 in 10,000. Applications for orphan designation are examined by the European Medicines Agency’s Committee for Orphan Medicinal Products. According to the Regulation (EC)…

Vaccines: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. What is the definition of a vaccine in your country? Danish legislation refers to the definition found in the European Pharmacopoeia. 2. What are the classifications of vaccines in your country? Vaccines are classified as medicines. The Danish legislation refers to the definition found in the European Pharmacopoeia. 3. Describe the pricing process for vaccines in your country (based on their…

Data Requirements: Denmark

04/03/2024

Gorrissen Federspiel

Denmark

Join industry executives in staying informed on the market access and HTA process in Denmark. 1. In addition to the clinical data obtained through clinical studies please list the data required for: a. Market approval / b. Pricing Decisions / c. Reimbursement Decisions a. Market approval Please see the detailed guidance on the Danish Medicines Agency’s website on applications for marketing authorisations: https://laegemiddelstyrelsen.dk/en/licensing/licensing-of-medicines/marketing-authorisation/application-for-marketing-authorisation/guidelines-for-new-applicants/ (in English). b. Pricing Decisions As mentioned above, the companies placing the medicinal products on the Danish…